Italia markets closed
Dow Jones
39.154,83 +42,67 (+0,11%) Nasdaq
17.741,60 +23,94 (+0,14%) Nikkei 225
39.667,07 +493,92 (+1,26%) EUR/USD
1,0681 -0,0034 (-0,32%) Bitcoin EUR
56.933,62 -1.363,45 (-2,34%) CMC Crypto 200
1.265,94 -17,84 (-1,39%)
NBIX Dec 2024 140.000 call
OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
In data: 03:59PM EDT. Mercato aperto.
| Chiusura precedente | 13,75 |
| Aperto | 13,75 |
| Denaro | 15,30 |
| Domanda | 17,70 |
| Prezzo d'esercizio | 140,00 |
| Scadenza | 2024-12-20 |
| Min-Max giorno | 13,75 - 13,75 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 1,04k |
GlobeNewswireSosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat
© 2024 Yahoo. Tutti i diritti riservati.